Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Change in Account Payables (2019 - 2025)

Pulmonx (LUNG) has disclosed Change in Account Payables for 7 consecutive years, with $121000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables fell 91.02% to $121000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.1 million, a 61.41% increase, with the full-year FY2024 number at $2.3 million, up 760.29% from a year prior.
  • Change in Account Payables was $121000.0 for Q3 2025 at Pulmonx, down from $2.1 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.6 million in Q3 2021 to a low of -$2.8 million in Q4 2021.
  • A 5-year average of $264894.7 and a median of $121000.0 in 2025 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: crashed 2111.11% in 2022, then skyrocketed 42900.0% in 2025.
  • Pulmonx's Change in Account Payables stood at -$2.8 million in 2021, then soared by 70.54% to -$830000.0 in 2022, then plummeted by 104.58% to -$1.7 million in 2023, then surged by 58.78% to -$700000.0 in 2024, then soared by 117.29% to $121000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Change in Account Payables are $121000.0 (Q3 2025), $2.1 million (Q2 2025), and $505000.0 (Q1 2025).